SMARTProbe”, a University College Cork and Tyndall National Institute technology was awarded €753K by Enterprise Ireland to continue technical and commercial development on a bioimpedance biopsy needle.
This biopsy device provides real-time diagnostic data to empower clinicians to make informed decisions during biopsy sampling by identifying benign and cancerous tissue. Millions of women around the world undergo breast biopsies following suspicious mammograms, waiting days to get results. Yet 80% of these breast biopsies are not indicative of cancer.
The SMARTProbe team is led by Dr Eric Moore, with Dr Anulika Justina Ugwah (AMRSC) moving into a commercial lead role in the project, and Dr Yineng (Ian) Wang as the technical lead. The group is supported by the HRB Clinical Research Facility in UCC, a breast cancer clinical team in Cork University Hospital, and UCC Innovation.
UCC Innovation expects SMARTProbe to spin out as a company in the next 3-5 years, following their regulatory and clinical approval for the cancer biopsy market.
https://www.linkedin.com/posts/ucc-innovation_successful-commercialisation-awards-to-ucc-activity-6967402976940281857-db7U?utm_source=share&utm_medium=member_desktop
Contacts
Sign up to receive CLISTEPROBE news & updates.
Email Contact us info@cliste-probe.com
353 (21)2346618
Sensing & Separation Group
School of Chemistry & Life Science Interface
Tyndall National Institute
University College Cork, Lee Maltings,
T12 R5CP Cork
